Stockscreener 앱 받기
0.5449
54.21%
-0.6451
시간 외 거래:
.55
0.0051
+0.94%
Aspire Biopharma Holdings Inc 주식(ASBP)의 최신 뉴스
Buzz Bomb Caffeine Partners with Interwest to Expand Retail Footprint - National Today
Aspire Biopharma's Buzz Bomb Caffeine Brand Partners with Interwest Brokerage - National Today
12 Health Care Stocks Moving In Wednesday's Intraday SessionAspire Biopharma Holdings (NASDAQ:ASBP), H - Benzinga
Aspire Biopharma Holdings, Inc. Announces LOI to Acquire Driver Controls Systems Business from Firefish Topco LLC - Minichart
Aspire Biopharma's Buzz Bomb Caffeine Company Partners with Interwest Brokerage to Accelerate Retail Expansion - USA Today
Buzz Bomb targets Utah, Idaho, Montana stores via Interwest deal - Stock Titan
Aspire Biopharma Signs LOI to Acquire DCS Unit - TipRanks
Aspire Biopharma signs non-binding letter of intent to acquire DCS unit - Investing.com
Aspire Biopharma Signs LOI to Acquire Driver Controls Systems for $30 Million - TradingView — Track All Markets
Aspire Biopharma (ASBP) signs non-binding $30M deal for DCS unit - Stock Titan
[EFFECT] Aspire Biopharma Holdings, Inc. SEC Filing - Stock Titan
Aspire Biopharma's Wholly Owned Subsidiary, Buzz Bomb Caffeine Company, Partners with Blue Shark Beverages to Expand Southern California Distribution - Peoria Journal Star
ASPIRE BIOPHARMA HOLDINGS IN (ASBP) Fundamental Analysis & Valuation - ChartMill
Aspire Biopharma Scales Consumer Division with Delivery of Two Million BUZZ BOMB(TM) Units Featuring Modernized Brand Identity - Bluffton Today
Aspire Biopharma Provides Q3 2025 Business Update - The Augusta Chronicle
Aspire Biopharma secures up to $21M in convertible preferred stock financing - MSN
159M ASBP (Nasdaq: ASBP) resale shares tied to $20M preferred deal - Stock Titan
ASBP Stock Price, Quote & Chart | ASPIRE BIOPHARMA HOLDINGS IN (NASDAQ:ASBP) - ChartMill
Aspire Biopharma's BUZZ BOMB(TM) Disrupts Energy Category with New Convenience Store Pack - Pocono Record
Aspire Biopharma Holdings: Innovative Patent-Pending Sublingual Drug Delivery & Product Pipeline Overview - Minichart
Aspire Biopharma (NASDAQ: ASBP) details sublingual pipeline and financings - Stock Titan
Aspire Biopharma Announces Reverse Stock Split - The Times Telegram
Aspire Biopharma Granted Extension by Nasdaq Hearing Panel to Regain Compliance with Continued Listing Requirements - Visalia Times-Delta
ASBP Technical Analysis | Trend, Signals & Chart Patterns | ASPIRE BIOPHARMA HOLDINGS IN (NASDAQ:ASBP) - ChartMill
Aspire Biopharma's Subsidiary to Feature BUZZ BOMB(TM) at The Health & Fitness Show 2026 - patriotledger.com
Aspire Biopharma Submits Pre-IND Meeting Request and Briefing Package to U.S. FDA for Sublingual Aspirin Product for Treatment of Suspected Acute Myocardial Infarction (Heart Attack) - Burlington Free Press
Aspire Biopharma: Disruptive Sublingual Drug Delivery Technology, Pipeline, and Patent Portfolio Overview 798289 - Minichart
Aspire Biopharma 10-K: Revenue $6.2K, Net Loss $24.48M - TradingView — Track All Markets
Reverse recap and sublingual pipeline reshape Aspire Biopharma (NASDAQ: ASBP) - Stock Titan
Aspire Biopharma Holdings, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Aspire Biopharma's Wholly Owned Subsidiary, Buzz Bomb Caffeine Company, to Showcase BUZZ BOMB(TM) Caffeine and its Innovative Sublingual Delivery Technology at The Sports & Active Nutrition Summit - The Patriot Ledger
ASBP Soars: Biotech Turbulence Fuels an Unexpected 17% Jump - bitget.com
Aspire Biopharma's Subsidiary, Buzz Bomb Caffeine Company, Appoints John Choe as Western Sales Director - ACCESS Newswire
Aspire Biopharma's Subsidiary Announces Agreement with TruLife Distribution to Drive National Retail Expansion - Black Hills Pioneer
Aspire Biopharma's Subsidiary Announces Retail Expansion Deal - National Today
Aspire Biopharma Plunges 19.5% on Intraday Freefall: What’s Fueling the Sharp Drop? - Bitget
2.69%
0.25%
자본화:
|
볼륨(24시간):